A concurrent 12-week exercise protocol alleviated the lipid metabolism disorders of IR and NAFLD, probably via PPAR-γ/CPT-1/MCAD signaling. The gene discussed is ACADM; the disease is metabolic dysfunction-associated steatotic liver disease.